Poster

TitelDatumKongress, Ort,

No difference in treatment continuation of different biologics in elderly patients >70 years compared to younger patients ≤65 years
2019EULAR, Madrid
Which factors influence achievement of treatment satisfaction in rheumatoid arthritis? 2019EULAR, Madrid
Comparing real-world retention rates in a matched cohort of rheumatoid arthritis patients who either remained on the etanercept originator or switched to a biosimilar 2019EULAR, Madrid
No confirmation of increased risk of idiopathic facial nerve palsy under tocilizumab 2019EULAR, Madrid
Erste Erfahrungen mit Baricitinib aus dem rheumatologischen Alltag2018 DGRh, Mannheim
Wie hoch ist der Einfluss von prognostisch ungünstigen Faktoren auf das Erreichen niedriger Krankheitsaktivität bei Patienten mit rheumatoider Arthritis?2018DGRh, Mannheim
Prognose der Herzinsuffizienz bei Patienten mit rheumatoider Arthritis2018DGRh, Mannheim
Der Einfluss von Adipositas und Geschlecht auf die Therapiewirksamkeit bei rheumatoider Arthritis hängt vom betrachteten Endpunkt ab2018 DGRh, Mannheim
Retentionsraten für Etanercept: Vergleich des Originals mit einem Biosimilar2018 DGRh, Mannheim
The prognosis of heart failure in patients with rheumatoid arthritis2018EULAR, Amsterdam
Influence of obesity and gender on drug effectiveness in rheumatoid arthritis depends on the outcome considered 2018EULAR, Amsterdam
Retention rates for Etanercept: comparing the original with a biosimilar2018 EULAR, Amsterdam
Switching from synthetic to biologic DMARDs – is there an insufficient use of methotrexate? 2017ACR, San Diego
Rates and risk factors of new-onset psoriasis under different biologic agents and conventional synthetic DMARD treatment
2017
EULAR, Madrid,
Early treatment response to csDMARD therapy in rheumatoid arthritis is a better predictor of low disease activity or treatment escalation at 12 and 24 months than autoantibodies or erosions
2017
EULAR, Madrid,
Unzureichende Therapie kardiovaskulärer Begleiterkrankungen ist ein wichtiger Risikofaktor für Schlaganfall bei RA-Patienten: eine gematchte Fall-Kontroll-Studie aus dem RABBIT Register
2016
DGRh, Frankfurt,
Tocilizumab ist ähnlich effektiv bei Patienten mit bis zu zwei vorherigen bDMARD Versagen wie in der Ersttherapie
2016
DGRh, Frankfurt
Perforationen des unteren Darmtrakts sind unter Tocilizumab häufiger als unter anderen Biologika- oder csDMARD-Therapien und präsentieren sich mit untypischen Symptomen
2016
DGRh, Frankfurt,

Initiation of biologic treatment over the past 15 years reflects changes in treatment strategies: results from the prospective cohort of the German biologics register RABBIT



2016
EULAR, London,

Tocilizumab is similarly effective in RA patients with no or up to two prior bDMARD failures: Results from the German prospective cohort study RABBIT



2016
EULAR, London,
Insufficient cardiovascular treatment  is a major risk factor for stroke in RA patients: a matched case-control study from the German biologics register RABBIT
2016
EULAR, London,

Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes



2015
ACR, San Francisco,
Tocilizumab is effective as 1st, 2nd and 3rd-line biologic DMARD in patients with RA
2015
ACR, San Francisco,
Do patients with congestive heart failure treated with biologics for RA have a lower risk of fatal outcome of serious infections?
2014
ACR, Boston,
Schwangerschaftsregister Rhekiss
2014
DGRh, Düsseldorf,
RA-Patienten mit einer Herzinsuffizienz haben ein hohes Risiko, an einer schwerwiegenden Infektion zu versterben
2014
DGRh, Düsseldorf,
Biologika in Monotherapie: Behandlungsoption für ältere RA Patienten?
2014
DGRh, Düsseldorf,
Biologic monotherapy: a treatment option for elderly RA patients with multimorbid conditions?
2014
EULAR, Paris,
Effectiveness of first, second or third biologic DMARDs – clinical characteristics are more important than choice of the substance
2014
EULAR, Paris,
Risk factors for Stroke in Patients with Rheumatoid Arthritis – Results from the German Biologics Register
2013
ACR, San Diego,
Zugang zu Biologika bei rheumatoider Arthritis in Deutschland 2001-2012
2013
DGRh, Mannheim,
Is there a downside in off-label use of rituximab? Three-year data from the German biologics register RABBIT
2013
EULAR, Madrid,
Physical and Mental Health in RA Patients Treated with Biologic DMARDs
2013
EULAR, Madrid,
Validierung des RABBIT Risikoscores für schwerwiegende Infektionen
2012
DGRh, Bochum,
Erwerbsminderung wegen Rheumatoider Arthritis: Rückgang der Inzidenz in Deutschland
2012
DGRh, Bochum,
Impact of different Biologic Agents on the Improvement of Fatigue
2012
ACR, Chicago,
Increased ability to meet occupational, home or leisure requirements in patients starting biologic agents
2012
ACR, Chicago,
Patienten, die eine Biologika-Therapie beginnen, verbessern deutlich ihre Fähigkeit, den üblichen Tätigkeiten in Beruf, Haushalt und Freizeit nachzugehen
2011
DGRh, München, 31.
Periprosthetic joint infections in RA patients treated with biologics or conventional DMARDs
2011
EULAR, London,
RA patients who are in remission according to the new ACR/EULAR criteria have a functional capacity equal to the general population
2011
EULAR, London,
Increasing Chance of Remission in Patients with Rheumatoid Arthritis
2010
ACR, Atlanta,
Influence of ESR on EULAR response rates in patients treated with tocilizumab. Results from the German biologics register RABBIT
2010
ACR, Atlanta
Die Chance auf Remission bei RA wächst
2010
DGRh, Hamburg
Effectiveness of treatment with rituximab depends on autoantibody status – results from 2 years of experience in the German biologics register RABBIT
2009
ACR, Philadelphia
Behandlung von RA-Patienten mit Abatacept – Daten aus dem RABBIT-Register
2009
DGRh, Köln,
Hohe Inzidenz von Pankreaskarzinomen bei RA-Patienten
2009
DGRh, Köln,
Increased incidence of pancreatic carcinoma in rheumatoid arthritis patients receiving leflunomide
2009
EULAR, Kopenhagen,
RA patients treated with Rituximab – routine care data of the German biologics register RABBIT
2008
ACR, San Francisco,
Behandlung von Patienten mit Rheumatoider Arthritis mit Rituximab – Daten aus dem RABBIT-Register
2008
DGRh, Berlin,
Kein erhöhtes Risiko maligner Tumore unter Biologika
2008
DGRh, Berlin,
Leflunomid erhöht das Risiko für das Auftreten einer peripheren Neuropathie bei Patienten mit RA
2008
DGRh, Berlin,
No increased risk of solid tumours in patients treated with biologics – a nested case-control study from the German biologics register RABBIT
2008
EULAR,Paris
RA patients with prior malignancy under treatment with biologics
2008
EULAR,Paris
Leflunomide is an acceptable combination partner for TNF inhibitors if methotrexate is not tolerated – results from the German biologics register
2007
ACR, Boston,
Schwangerschaften bei RA-Patientinnen unter einer Therapie mit Biologika – Daten aus dem RABBIT-Register
2007
DGRh, Hamburg,
Relapse rates during the first year after withdrawal of anti-TNF treatment because of remission
2007
EULAR,Barcelona
Long-term continuation of anti-TNF treatment in combination with either methotrexate or leflunomide compared to monotherapy – results from the German biologics register
2007
EULAR,Barcelona
Time to relapse in RA patients withdrawn from anti-tnf treatment because of remission
2007
ACR, Washington DC,
Wie lange hält bei RA Patienten eine Remission nach dem Absetzen von Adalimumab, Etanercept oder Infliximab noch an?
2006
DGRh, Wiesbaden,
Biologics increase the chance of remission by two. Results from the German biologics register
2006
EULAR, Amsterdam,
Significantly higher chance of ‚functional remission‘ or physical independence in RA patients receiving biologics. Results from the German biologics register
2006
EULAR, Amsterdam,
Adherence to published guidelines on TB screening before the start of treatment with biologics in Germany
2006
EULAR, Amsterdam,
Infections in RA patients treated with infliximab or etancercept
2005
EULAR, Wien,
No relevant escalation in dosage of infliximab or other biologic agents over 12 months of treatment – Results from the German Biologic Register
2004
ACR, San Antonio
Long Term Observation of Biologics in Germany – Which Patients Are Treated with Biologic Compounds?
2004
EULAR, Berlin
Long Term Observation of Biologics in Germany – Safety Data after 6 Months
2004
EULAR, Berlin
Langzeitbeobachtung der Behandlung der rheumatoiden Arthritis mit Biologika – Unerwünschte Ereignisse im ersten Therapiehalbjahr
2003
DGRh, Frankfurt,
Langzeitbeobachtung der Behandlung der rheumatoiden Arthritis mit Biologika in Deutschland: Behandlungsanamnese und aktuelle Therapie
2003
DGRh, Frankfurt,